CoNCERT secures $37 million in series C funding

The company intends to use the proceeds to further advance its deuterium chemistry platform and product pipeline. The financing was led by a public equity institutional investor and included participation from Adage Capital Management, SR One (GlaxoSmithKline’s independent healthcare venture fund), Mediphase Venture Partners, and Westfield Capital Management.

Roger Tung, president and CEO of CoNCERT Pharmaceuticals, said: “We are building a strong investor base comprising both top-tier venture capital and leading crossover funds. We believe the caliber of CoNCERT’s investors speaks to the strength of our business strategy and leadership team.”